{
  "id": "cluster_1_doc2",
  "content": "Policy update HX-882TN effective March 2024 modifies coverage criteria for biologic treatments of refractory orbital infections. Requires prior authorization documentation including failed conventional antibiotic regimens. Applies specifically to Brightshore Medical Center formulary under network agreement NH-1047. Exceptions may apply for patients with concurrent autoimmune conditions per new rheumatology guidelines.",
  "metadata": {
    "format": "policy_document"
  }
}